[ad_1]
Biopharma startup
After surging to record levels in 2024, enterprise investments in girls’s well being firms plummeted final 12 months. Some business watchers assume a shift in the best way entrepreneurs and startups are advertising and marketing themselves may spark a extra sustainable rebound.
A latest report from Silicon Valley Financial institution, an funding agency that tracks startup funding and a division of First Residents Financial institution, put the state of affairs in context.
In that report, SVB discovered that the full enterprise funding flowing into girls’s well being firms — which embody makers of therapeutics, gadgets and well being applied sciences — plummeted from $3.2 billion in 2024 to round $2 billion in 2025. The share of healthcare enterprise offers these firms have been concerned in fell from 7.4% to five.7% over that timeframe.
Biopharma startups have been hit significantly exhausting, with enterprise funding numbers plunging from $1.3 billion to $610 million, in line with the SVB report.
The report’s authors argued that girls’s well being firms have been swept up in a broader change throughout the healthcare ecosystem. Buyers have more and more turned their consideration to extra established firms that appear to be surer bets.
“There is a shift in healthcare investing as a complete,” mentioned Megan Scheffel, head of life sciences and healthcare for SVB, in an interview with BioPharma Dive.
The ripple results are being felt by girls’s well being startups, Scheffel mentioned. Younger firms must show excess of they beforehand did, with founders needing to “acquire tangible early traction” to safe early funding.
Fewer firms are assembly that bar, main much less and fewer to graduate to their subsequent spherical. SVB decided that, because of this, traders have been pouring smaller quantities into earlier-stage firms.
“I feel [companies] wish to elevate large rounds; on the similar time, you’ve to have the ability to do extra with these rounds,” she mentioned.
These firms are additionally competing with AI-centric startups which are “sucking up numerous the air within the room,” Payal Divakaran, of funding agency.
406 Ventures, mentioned within the report. AI drug discovery investments are lifting enterprise funding totals within the biopharmaceutical area, however girls’s well being firms aren’t but capitalizing the best way the remainder of healthcare is.
Scheffel refers to those sequence of shifts as a “reset” that’s recalibrating “the place and the way capital strikes via the market.”
“Whereas preliminary capital stays obtainable, the baseline to safe it has shifted dramatically,” she mentioned. “Progress that was the province of Sequence A is now required to boost a Seed spherical.”
“The fundraising is down, the valuations are completely different, and so [companies are] doing extra with much less,” she added.
They’re additionally advertising and marketing themselves in a different way, she and others say.
When Scheffel’s crew started monitoring girls’s well being investments just a few years in the past, the enterprise offers they noticed have been primarily targeted on reproductive healthcare, a time period encompassing contraception, maternal well being points and fertility.
Drug growth there and for different situations primarily affecting girls has been traditionally underfunded, as longstanding research gaps have made for difficult investment propositions.
“Ladies’s well being is a class that, to some extent, has been out of favor with conventional biotech traders,” mentioned Douglas Tsao, a senior analyst and managing director at funding agency H.C. Wainwright.
Some latest drug merchandise tailor-made to girls haven’t been “commercially profitable” both, Tsao added.
Veozah, a non-hormonal remedy Astellas Pharma developed for menopause, launched in 2023 and struggled to take off following its 2023 launch resulting from a scarcity of demand and reimbursement obstacles. Gross sales reached about $300 million final 12 months and totaled close to $100 million within the first fiscal quarter of 2026. Bayer hasn’t but broken out sales for a competing drug, Lynkuet, authorised final 12 months.
In line with Scheffel, girls’s well being firms at the moment are altering their funding pitches. The “addressable market” they’re chasing is greater, involving situations like melancholy, weight problems or coronary heart illness that have an effect on each ladies and men — however affect girls in a different way, disproportionately or uniquely.
“Folks don’t come out and say I’m serving girls, as a result of they’re not solely serving girls, they’re serving women and men,” Scheffel mentioned. “It’s like a advertising and marketing problem greater than it’s the rest.”
Some traders have been rewarded for betting on these sorts of firms. SVB’s report famous how 18 girls’s well being firms have been acquired in 2025, a small dip from the 21 purchases a 12 months prior. In a particularly active 2026 for biopharmaceutical dealmaking, one of many 12 months’s largest buyouts concerned a girls’s well being firm, Organon.
Notably, 14 girls’s well being startups went public in 2025 after zero did in 2024. And extra “unicorns” price at the least a billion {dollars} — amongst them Flo Well being, Midi Well being and Maven — are rising, too, in line with SVB.
Tsao notes that a few of this exercise is concentrated round “low barrier to entry” elements of ladies’s well being, resembling diagnostics or testing companies that may be dropped at market extra shortly and cheaply than a brand new drugs.
Firms may speed up funding additional by adopting AI extra, Scheffel mentioned.
A Pew Analysis Heart ballot cited in SVB’s report illustrated that girls are much less possible than males to imagine AI can enhance their healthcare. However Scheffel identified that many ladies’s well being firms are compiling troves of knowledge on girls who’re pregnant or present process menopause. That data may very well be helpful in unearthing future therapies for underserved conditions.
“There’s a fairly large alternative for change,” Scheffel mentioned.
[ad_2]
